Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination drug** consisting of *docosahexaenoic acid* (DHA) and *minoxidil*. **Docosahexaenoic acid** is an omega-3 fatty acid, typically used as a dietary supplement for general health and sometimes included in formulations for skin and hair health. **Minoxidil** is an antihypertensive small molecule drug and peripheral vasodilator, FDA-approved for the treatment of severe hypertension and for topical use in the treatment of androgenetic alopecia (pattern hair loss). Minoxidil’s mechanism involves lengthening the anagen (growth) phase of the hair cycle and increasing blood flow to hair follicles, promoting hair growth[1][2][3][4]. The rationale for combining DHA and minoxidil would be to harness potential synergistic effects on hair and scalp health, though no specific branded or standardized pharmaceutical product containing both agents appears in current regulatory databases or literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on docosahexaenoic acid + minoxidil.